Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study

被引：0
|
作者：
Catamero, Donna [1 ]
Benito, Patricia Blazquez [2 ]
Shenoy, Samantha [3 ]
Chastain, Katherine [4 ]
Kruyswijk, Sandy [5 ]
机构：
[1] Mt Sinai Hlth Syst, New York, NY USA
[2] Univ Hosp Salamanca, Salamanca, Spain
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Janssen Res & Dev, Raritan, NJ USA
[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NSP-05
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [1] MANAGING CYTOKINE RELEASE SYNDROME IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXPERIENCE WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY
    Catamero, Donna
    Blazquez, Patricia
    Shenoy, Samantha
    Chastain, Katherine
    Kruyswijk, Sandy
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [2] Nursing Considerations for Cytokine Release Syndrome in Relapsed/ Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study
    Catamero, Donna
    Benito, Patricia Blazquez
    Shenoy, Samantha
    Doyle, Margaret
    Fowler, Jessica
    Kobos, Rachel
    Banerjee, Arnob
    Kruyswijk, Sandy
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (03)
  • [3] MANAGING INFECTION RISK IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA: NURSING EXPERIENCE WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY
    Kruyswijk, Sandy
    van de Donk, Niels
    Doyle, Margaret
    Chastain, Katherine
    Trancucci, Danielle
    Catamero, Donna
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [4] Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Mateos, Maria Victoria
    Nooka, Ajay
    Banerjee, Arnob
    Kobos, Rachel
    Pei, Lixia
    Qi, Ming
    Verona, Raluca
    Doyle, Margaret
    Smit, Jennifer
    Sun, Weili
    Trancucci, Danielle
    Uhlar, Clarissa
    van de Donk, Niels W. C. J.
    Rodriguez, Cesar
    CANCER, 2023, 129 (13) : 2035 - 2046
  • [5] Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Cortes-Selva, Diana
    Perova, Tatiana
    Skerget, Sheri
    Vishwamitra, Deeksha
    Stein, Sarah
    Boominathan, Rengasamy
    Lau, Onsay
    Calara-Nielsen, Karl
    Davis, Cuc
    Patel, Jaymala
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa
    Kobos, Rachel
    Goldberg, Jenna
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad Z.
    Bahlis, Nizar J.
    van de Donk, Niels W. C. J.
    Verona, Raluca I.
    BLOOD, 2024, 144 (06) : 615 - 628
  • [6] Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
    Moreau, Philippe
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Olyslager, Yunsi
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Kobos, Rachel
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (12) : 811 - 818
  • [7] Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 study
    Catamero, Donna
    Benito, Patricia Blazquez
    Shenoy, Samantha
    Chastain, Katherine
    Banerjee, Arnob
    Qi, Keqin
    Skerget, Sheri
    Doyle, Margaret
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S315 - S315
  • [8] Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
    Rosinol, Laura
    Garfall, Alfred
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    van de Donk, Niels
    Matous, Jeffrey
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S84 - S85
  • [9] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Nooka, Ajay K.
    Rodriguez, Cesar
    Mateos, Maria Victoria
    Manier, Salomon
    Chastain, Katherine
    Banerjee, Arnob
    Kobos, Rachel
    Qi, Keqin
    Verona, Raluca
    Doyle, Margaret
    Martin, Thomas G.
    van de Donk, Niels W. C. J.
    CANCER, 2024, 130 (06) : 886 - 900
  • [10] Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Xin Miao
    Liviawati S. Wu
    Shun Xin Wang Lin
    Yan Xu
    Yang Chen
    Yuki Iwaki
    Rachel Kobos
    Tara Stephenson
    Kristy Kemmerer
    Clarissa M. Uhlar
    Arnob Banerjee
    Jenna D. Goldberg
    Danielle Trancucci
    Amit Apte
    Raluca Verona
    Lixia Pei
    Rachit Desai
    Kathleen Hickey
    Yaming Su
    Daniele Ouellet
    Mahesh N. Samtani
    Yue Guo
    Alfred L. Garfall
    Amrita Krishnan
    Saad Z. Usmani
    Honghui Zhou
    Suzette Girgis
    Targeted Oncology, 2023, 18 : 667 - 684
12345